Immunovia Publishes Full Year Report for 2022
October-December 2022 · Net sales amount kSEK 502 (305) divided by sales of tests kSEK 190 (278) and royalties kSEK 312 (27). · Net earnings amount MSEK -67 (-47) and earnings per share before and after dilution were SEK -2.97 (-2.08). · Cash Flow from operating activities amount MSEK -51 (-50). · Cash and equivalents at the end of the period amounted to MSEK 106 (287). · On October 12, the Company announced a positive update on its physician experience program with IMMray™ PanCan-d. Thus far the program has included 23 high risk surveillance centers around the U.S. thus